DNTH103

DRUG3 trials

Sponsors

Dianthus Therapeutics Inc.

Conditions

Chronic Inflammatory Demyelinating PolyneuropathyGeneralized Myasthenia GravisMultifocal Motor Neuropathy

Phase 2

A PHASE 2, RANDOMIZED, BLINDED, PLACEBOCONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS (MAGIC)

RecruitingCTIS2024-512865-15-00

Dianthus Therapeutics Inc.Generalized Myasthenia Gravis

Start: 2024-09-03Target: 54Updated: 2025-10-27

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults with Multifocal Motor Neuropathy (MOMENTUM)

RecruitingCTIS2024-513128-40-00

Dianthus Therapeutics Inc.Multifocal Motor Neuropathy

Start: 2025-02-06Target: 11Updated: 2026-01-12

Phase 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

RecruitingCTIS2024-517529-26-00

Dianthus Therapeutics Inc.Chronic Inflammatory Demyelinating Polyneuropathy

Start: 2025-08-04Target: 156Updated: 2026-01-26